Form D · Other Health Care

Ascus Biosciences, Inc.

San Diego, CA · CIK 0001672679

Offering snapshot reported Jun 13, 2019 · SEC filing

Reported sold
$5M
Offering amount: $5M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 31, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 13, 2019Initial$5,000,000No comparison10SEC filing
Sep 5, 2018Initial$6,000,000No comparison6SEC filing
Jul 11, 2017Initial$5,000,000No comparison9SEC filing
Apr 26, 2016Initial$12,694,128No comparison9SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-341832
Consists of Convertible Promissory Notes convertible into shares of Preferred Stock of the Issuer.

Source: Form D, filed Jun 13, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mallory Embree Director, Executive
Peter Innes Director
Jim Kim Director
Michael Seely Director, Executive
Thad Simons Director
Erik Torgerson Director

Issuer details

Industry: Other Health Care (See others in industry)

Address:
6450 Lusk Blvd Suites E109/209
San Diego, CA, 92121